IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Industrial Alliance Investment Management Inc.

Industrial Alliance Investment Management Inc. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 3.0% during the third quarter, Holdings Channel reports. The firm owned 5,190 shares of the company’s stock after purchasing an additional 150 shares during the period. Industrial Alliance Investment Management Inc.’s holdings in IDEXX Laboratories were worth $1,691,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Ronald Blue Trust Inc. purchased a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $34,000. Carolinas Wealth Consulting LLC raised its stake in shares of IDEXX Laboratories by 42.3% in the 2nd quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the period. Riverview Trust Co raised its stake in shares of IDEXX Laboratories by 202.8% in the 3rd quarter. Riverview Trust Co now owns 109 shares of the company’s stock valued at $36,000 after acquiring an additional 73 shares during the period. Atlas Capital Advisors LLC purchased a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $44,000. Finally, Advanced Research Investment Solutions LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $52,000. Hedge funds and other institutional investors own 87.90% of the company’s stock.

IDEXX Laboratories Stock Up 2.0 %

Shares of IDEXX Laboratories stock opened at $474.11 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 1.14. The firm has a market cap of $39.30 billion, a P/E ratio of 59.04, a P/E/G ratio of 2.67 and a beta of 1.18. IDEXX Laboratories, Inc. has a fifty-two week low of $317.06 and a fifty-two week high of $560.92. The business has a 50-day moving average price of $481.01 and a 200 day moving average price of $413.89.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last announced its quarterly earnings data on Monday, February 6th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.92 by $0.13. The firm had revenue of $828.60 million during the quarter, compared to analyst estimates of $820.91 million. IDEXX Laboratories had a return on equity of 124.51% and a net margin of 20.17%. IDEXX Laboratories’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.89 earnings per share. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 9.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of a number of analyst reports. Atlantic Securities upped their price objective on shares of IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a research report on Tuesday, February 7th. Barclays lifted their target price on IDEXX Laboratories from $582.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 8th. TheStreet raised IDEXX Laboratories from a “c+” rating to a “b-” rating in a research report on Friday, November 25th. StockNews.com began coverage on IDEXX Laboratories in a research report on Thursday. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $525.00 to $550.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 7th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $514.75.

Insider Activity

In other news, SVP Kathy V. Turner sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of $505.04, for a total transaction of $505,040.00. Following the completion of the transaction, the senior vice president now directly owns 6,941 shares of the company’s stock, valued at $3,505,482.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Kathy V. Turner sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of $505.04, for a total transaction of $505,040.00. Following the completion of the transaction, the senior vice president now directly owns 6,941 shares of the company’s stock, valued at $3,505,482.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kathy V. Turner sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 14th. The shares were sold at an average price of $504.59, for a total value of $1,009,180.00. Following the transaction, the senior vice president now directly owns 7,380 shares of the company’s stock, valued at $3,723,874.20. The disclosure for this sale can be found here. Corporate insiders own 2.06% of the company’s stock.

IDEXX Laboratories Company Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.